Cycle Pharmaceuticals’ NITYR (nitisinone) tablets receives marketing authorization in Chile

Cycle Pharmaceuticals’ NITYR (nitisinone) tablets receives marketing authorization in Chile

November 22nd, 2018|0 Comments

Longer shelf life for NITYR (nitisinone) tablets for HT-1 in the U.S. granted by the FDA

November 19th, 2018|0 Comments

Cycle Pharmaceuticals Receives Approval for Updated Infant Administration for NITYR (nitisinone) Tablets for HT-1 in U.S.

November 12th, 2018|0 Comments

Cycle Pharmaceuticals Receives FDA Approval for Ketorolac Tromethamine Tablets in the U.S.

August 29th, 2018|0 Comments

Aprecia Pharmaceuticals and Cycle Pharmaceuticals Partner to Develop 3D-Printed Orphan Drugs

December 12th, 2017|0 Comments

  • NITYR

Cycle Pharmaceuticals launches free trial of NITYR in the US and Partners with Cambrooke Therapeutics to Support HT-1 Patients’ dietary needs

November 10th, 2017|0 Comments

Cycle Pharmaceuticals Receives FDA Approval and Launches Ketorolac Tromethamine Injection 30mg/mL in the U.S.

September 19th, 2017|0 Comments

Cycle Pharmaceuticals Partners with Cardinal as the Logistic Provider for Nityr in U.S.

August 7th, 2017|0 Comments

Cycle Pharmaceuticals Partners with Diplomat to Dispense NityrTM in U.S.

August 3rd, 2017|0 Comments

Cycle Pharmaceuticals Receives FDA Approval of Nityr™ (nitisinone) Tablets for Treatment of HT-1

August 1st, 2017|0 Comments

First recommendation for HT-1 treatment in Quebec by INESSS

June 2nd, 2017|0 Comments

CYCLE Pharmaceuticals, The University of Cambridge and King’s College London Partner to Repurpose PARP Inhibitor Drugs for Vascular Disease

December 19th, 2016|0 Comments

FOLLOW US
WHY CYCLE PHARMA

We target market imbalance where we can better serve patient health needs by innovating drugs

More About Cycle